SLAS Europe round-up
DDW’s Reece Armstrong looks at the latest announcements that came out of SLAS Europe.
Contract research organisation (CRO) Nanoworx announced its nanomedicine development and optimisation services at this year’s SLAS Europe. The CRO’s new service is designed for academic and industry partners and is tailored to nanoparticle design and prototyping, nanomedicine high-throughput library construction and screening, nanomedicine production at scale, and in vitro assay testing.
Dr Makri-Pistikou, Co-founder and COO at Nanoworx, said: “With our unique knowledge and highly-skilled team, Nanoworx empowers clients to unlock the transformative potential of nanomedicine. We stand out by combining state-of-the-art facilities with a client-centric approach that builds lasting capabilities.”
At SLAS Europe, ORYL Photonics introduced its first platform designed for the measurement of solubility and aggregation of drug molecules. The company’s ORYL F1 is an automated laser-based platform that enables researchers to make faster decisions and gain a deeper understanding of their samples, which is essential for reducing drug development and production costs.
The instrument is based on second harmonic scattering, a laser-technology known for its sensitivity in probing the structure of materials at molecular level, and for the study of particles in liquids. The platform has an automated format suited to 96 and 384 well-plates.
“We are very happy to officially launch today our first instrument for the life science industry. This is the first platform dedicated to sensitive and high-throughput solubility and aggregation measurement, that requires minimal amount of sample,” shared Orly Tarun, CEO & Co-founder of ORYL Photonics.
Molecular Devices launched a new system to assist teams in the picking, plating and analysing of microbial colonies.
The company’s QPix FLEX Microbial Colony Picking System has been designed to automate and streamline multi-step microbial screening workflows, reducing manual labour and saving time. The system supports a wide range of research areas, including microbial strain engineering and microbiome research, and ensures complete sample tracking and traceability for reliable results.
“This multifunctional, integrated platform streamlines microbiology workflows and boosts productivity with advanced multimodal imaging and high-efficiency picking, making it ideal for small labs or challenging microbes,” said Mary Duseau, President of Molecular Devices. “It reflects our commitment to enabling all scientists—regardless of lab size—to innovate faster, scale up more confidently, and achieve scientific breakthroughs in synthetic biology, microbiome research, and beyond.”
MGI Tech unveiled its latest liquid handling system at SLAS Europe. The company showcased its PrepALL Flexible Liquid Handling Platform which has been designed to simplify complex laboratory tasks and maintain enterprise-level performance – without the high costs typically associated with traditional systems. The system leverages advanced vision-based AI and is suited to applications such as nucleic acid extraction, plasmid construction, sample preparation, and NGS library prep.
MGI Tech says it designed to platform with global accessibility in mind, addressing barriers such cost and complexity through a scalable, modular design and open APIs.
“PrepALL represents a major leap in lab automation, giving labs of all sizes the ability to streamline complex workflows with unmatched affordability and reliability. It’s a bold step in our mission to democratise cutting-edge tools and accelerate scientific discovery worldwide,” said Dr Christian Zimmerman, VP of Sales at MGI Europe and Africa.
Amphista Therapeutics presents its approach to constructing novel, orally bioavailable Targeted Glue protein degraders with mechanisms of action distinct from traditional CRBN/VHL approaches using its Eclipsys platform. The presentation at SLAS Europe highlighted how the company’s Eclipsys platform could help identify “fast, potent, and selective degraders against previously undruggable targets in oncology and other therapeutic areas,” explained Simon Gilbert, Presenting Author and Associate Director Discovery Biology at Amphista Therapeutics.
Amphista’s unique medicinal chemistry creates a novel interface on the target protein that is recognised by the E3 ligase most effective in driving its degradation. Notably the ligase engaged is not predefined but rather chosen by the target protein.
“This novel and distinct approach to rationally design Targeted Glues demonstrates Amphista’s deep capabilities, opening new possibilities for patients,” Gilbert added.
The platform was highlighted in the presentation using a hit identification screen for an oncology target that generated diverse, potent hits. Amphista’s scientists successfully deconvoluted the degrader mechanism of action and identified promising candidates for further development through cryo-EM enabled structure-based drug discovery.
